In a recent case series of 135 patients receiving ruxolitinib (JAK1/JAK2 inhibitor) [44], 8 developed symptomatic coccidioidomycosis; 4 had coccidioidomycosis preceding ruxolitinib, and each had primary pulmonary disease while on therapy. Here, JAK2 is linked to coccidioidomycosis.